The opportunities and challenges of the disease-modifying immunotherapy for type 1 diabetes: a systematic review and meta-analysis
In conclusion, nonantigen-based immunotherapies were associated with a preservation of 2h and 4h C-peptide AUC in patients with T1D when compared with the controls, which was mainly driven by the effects of TNF-a inhibitor and T cell-targeted therapy. Both nonantigen-based immunotherapies and antigen-based immunotherapies tended to reduce the daily insulin dosage in patients with T1D when compared with the controls. However, they did not contribute to a substantial improvement in HbA1c or FBG. Both nonantigen-based immunotherapies and antigen-based immunotherapies were well tolerated with not increased risk of hypoglycemia in patients with T1D.PMID:38531504 | DOI:10.1016/j.phrs.2024.107157
Source: Cell Research - Category: Cytology Authors: Chu Lin Suiyuan Hu Xiaoling Cai Fang Lv Wenjia Yang Geling Liu Xiaolin Yang Linong Ji Source Type: research
More News: Clinical Trials | Cytology | Diabetes | Diabetes Type 1 | Endocrinology | Immunotherapy | Insulin